Skip to main content
OpenTrials
Completed

NCT Number: NCT00598403

Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis

The main objective of the study is to comparatively assess the efficacy and tolerability of the drugs under study in the treatment of acute uncomplicated cystitis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

General Hospital of Chest Disease of Athens, Athens, Greece

Loading trial locations.

About this study

Urinary tract infections (UTI) are one of the most frequent reasons of surgery visits in Primary Care. More than 95 percent of UTIs are monomicrobial, although the microorganisms implied are varied, and the range of effective drugs could be extensive. The species most frequently isolated is Escherichia coli, with prevalence ranking between 85 and 90 percent of documented cases. E. coli has developed resistance to different antibiotics. Cefditoren is situated as a good candidate for the treatment of uncomplicated UTIs due to its spectrum of activity against E. coli. The study has been designed in accordance with the guidelines and recommendations in force to assess the efficacy of cefditoren pivoxil against ciprofloxacin, a drug which despite the increasing rate of resistance in some countries, continues to be a drug of choice for the treatment of uncomplicated UTIs.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Non-pregnant adult females (>= 18)
  • Clinical signs and symptoms of uncomplicated acute cystitis (dysuria, urgency, frequency, suprapubic pain) with symptoms starting <=72 hours prior the study entry
  • Positive pre-treatment clean-catch midstream urine culture (>= 103 CFU/ml) and pyuria (10 leukocytes/mm3 or more than 5 leukocytes/field 40x magnification) within the 48 hours prior to inclusion in the study
  • In vitro susceptibility testing of the isolated uropathogen to the drugs under study
  • Written informed consent

Exclusion criteria

  • Males
  • Woman who are pregnant, nursing or not using a medically accepted, effective method of birth control
  • Three or more episodes of uncomplicated acute infections of the urinary tract during the past 12 months
  • Symptoms starting >4 days prior to admission
  • Body temperature >= 38.3ºC, back pain, chills or other manifestations suggestive of upper urinary infection
  • Evidence of structural or functional alterations of the urinary tract, such as calculi, stenosis, primary renal disease (eg. polycystic renal disease) or neurogenic bladder
  • Underlying disease predisposing to complicated urinary tract infections such as diabetes mellitus, immunosuppression, leucopenia, heart insufficiency, liver impairment and neoplastic processes

Treatment and study plan

cefditoren pivoxil

Drug

400 mg, oral, single dose during 3 days

Other names: Meiact, Spectracef, Telo

Ciprofloxacin

Drug

250 mg, oral, twice a day for 3 days

Other names: Ciprofloxacino Mabo

Primary outcomes

  1. Microbiological efficacy

    Time frame: 5-9 days post-therapy

Secondary outcomes

  1. Clinical efficacy

    Time frame: 5-9 days post-therapy

Sponsors and collaborators

Lead sponsor

Tedec-Meiji Farma, S.A.

Industry

Registry information

Official study title

Multicentre, Prospective, Comparative, Randomized, Double-blind, Double-dummy Study to Assess the Efficacy and Safety of Cefditoren Pivoxil vs. Ciprofloxacin in Uncomplicated Acute Cystitis

Important dates

Study start
2007
Primary completion
2009
Study completion
2010
First posted
Jan 21, 2008
Registry last updated
Jun 29, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.